Cystic Fibrosis Foundation Risk Report

📜 Innovation & R&D

The Cystic Fibrosis Foundation has been active in funding and driving innovation aimed at improving treatments for cystic fibrosis. Key efforts include significant investments in gene therapy and breath detection technologies. These initiatives demonstrate commitment to advancing medical research and innovation.

• On 🗓 November 18, 2024, the Cystic Fibrosis Foundation invested up to $15 million in ReCode Therapeutics to develop gene editing therapy.
• The foundation granted $5 million to the Cleveland Clinic for lung transplant research 🗓 May 29, 2025.
• Owlstone Medical received up to $2.3 million from the foundation to develop a breath test for Pseudomonas aeruginosa detection 🗓 April 22, 2025.
• On 🗓 March 15, 2023, the foundation funded nanoparticle delivery research for the lungs to enhance cystic fibrosis treatment.

🏅 Awards & Recognition

The foundation has been acknowledged for its efforts and partnerships in supporting cystic fibrosis patients and research. Such recognition underscores its leadership and impact in the healthcare sector.

• UCSF Fresno Cystic Fibrosis Center was recognized for aiding patients to stay at home for care 🗓 April 9, 2025.
• The Luling family was highlighted for raising money for research efforts 🗓 April 3, 2025.

The Cystic Fibrosis Foundation's robust investment in medical research and development of innovative treatments, alongside consistent recognition, exemplifies its valuable contribution to healthcare. These actions not only enhance care quality but also reinforce the foundation's reputation as a pivotal player in combatting cystic fibrosis.